¸ñÀû: Our study aimed to explore the role of the potassium channel KCNK1 in
head and neck squamous cell carcinoma, focusing on its impact on tumor
growth, invasion, and metastasis. We also investigated the therapeutic
potential of quinidine, a known KCNK1 inhibitor, in both in vitro cell
lines and a zebrafish patient-derived xenograft (PDX) model. ¹æ¹ý:We established primary cell cultures from head and neck cancer tissues
and employed the FaDu cell line for in vitro studies, modulating KCNK1
expression through overexpression and knockdown techniques. We evaluated
cell migration, invasion, and proliferation. Additionally, we developed
a zebrafish PDX model to assess the impact of quinidine on tumor growth
and metastasis in vivo. RNA sequencing and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analyses were conducted to elucidate the
molecular mechanisms underlying the role of KCNK1 in cancer progression. °á°ú:Overexpression of KCNK1 in FaDu cells resulted in enhanced cell
migration and invasion, whereas its knockdown diminished these
processes. In the zebrafish PDX model, quinidine markedly inhibited
tumor growth and metastasis, demonstrating a significant reduction in
tumor volume and micrometastasis rates compared to the control groups.
The molecular analyses indicated that KCNK1 plays a role in critical
signaling pathways associated with tumor growth, such as the Ras and
MAPK pathways. °á·Ð:Our findings highlight the critical role of KCNK1 in promoting tumor
growth and metastasis in head and neck cancer. The inhibitory effect
of quinidine on tumor progression in the zebrafish PDX model
highlights the therapeutic potential of targeting KCNK1. These results
suggest that KCNK1 could serve as a valuable therapeutic target for
head and neck cancer, warranting further investigation into treatments
that target KCNK1. |